Claims
- 1. Prostaglandins E represented by a general formula:
- in which
- X represents: ##STR46## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydroxyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group,
- in which the C.sub.2 -C.sub.3 bond is a single or a double bond.
- 2. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR47## in which represents: ##STR48## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydroxyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group,
- in which the C.sub.2 -C.sub.3 bond is a single or a double bond.
- 3. Prostaglandins E represented by a general formula: ##STR49## in which X represents: ##STR50## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydrogen atom or a methyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group,
- in which the C.sub.2 -C.sub.3 bond is a single or a double bond.
- 4. Prostaglandins E as described in claim 3, being 13,14-dihydro-15-keto-5,6-dehydro-20-methoxy-PGE.sub.2 or alkyl ester thereof.
- 5. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR51## in which X represents: ##STR52## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydrogen atom or a methyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group,
- in which the C.sub.2 -C.sub.3 bond is a single or a double bond.
- 6. An anti-ulcer composition as described in claim 5, wherein the prostaglandin E is 13,14-dihydro-15-keto-5,6-dehydro-20-methoxy-PGE.sub.2 or alkyl ester thereof.
- 7. Prostaglandins E represented by a general formula: ##STR53## in which X represents: ##STR54## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydrogen atom or a methyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond,
- in which the C.sub.2 --C.sub.3 bond is a double bond.
- 8. Prostaglandins E as described in claim 7, being 13,14-dihydro-15-keto-.DELTA..sup.2 -PGE.sub.2 or alkyl ester thereof.
- 9. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR55## in which X represents: ##STR56## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydrogen atom or a methyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond,
- in which the C.sub.2 -C.sub.3 bond is a double bond.
- 10. An anti-ulcer composition as described in claim 9, wherein the prostaglandin E is 13,14-dihydro-15-keto-.DELTA..sup.2 -PGE.sub.2 or alkyl ester thereof.
- 11. Prostaglandins E represented by a general formula: ##STR57## in which X represents: ##STR58## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a methyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond,
- in which the C.sub.2 -C.sub.3 bond is a single bond.
- 12. Prostaglandins E as described in claim 11, wherein R.sub.5 is a methyl group.
- 13. Prostaglandins E as described in claim 11, wherein R.sub.6 is a C.sub.6 -C.sub.9 alkyl group.
- 14. Prostaglandins E as described in claim 11, wherein R.sub.6 is a hexyl group.
- 15. Prostaglandins E as described in claim 11, wherein the carboxyl group on the terminal position of the .alpha.-chain is esterified with an alkyl group.
- 16. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR59## in which X represents: ##STR60## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a methyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond,
- in which the C.sub.2 -C.sub.3 bond is a single bond.
- 17. An anti-ulcer composition as described in claim 16, wherein R.sub.5 is a methyl group.
- 18. An anti-ulcer composition as described in claim 16, wherein R.sub.6 is a C.sub.6 -C.sub.9 alkyl group.
- 19. An anti-ulcer composition as described in claim 16, wherein R.sub.6 is a hexyl group.
- 20. An anti-ulcer composition as described in claim 16, wherein the carboxyl group on the terminal position of the .alpha.-chain is esterified with an alkyl group.
- 21. An anti-ulcer composition as described in claim 16, wherein the prosaglandin E is 13, 14-dihydro-15-keto-6R,S-methyl-PGE.sub.2 alkyl ester.
- 22. A method of treating an ulcer comprising administering to a patient in need of such treatment an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR61## in which X represents ##STR62## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 represents: a hydrogen atom, a methyl group or a hydroxyl group;
- R.sub.5 represents: a hydrogen atom or a methyl group; and
- R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, in which the C.sub.2 -C.sub.3 bond is a single or a double bond; provided that when R.sub.4 and R.sub.5 are each hydrogen, R.sub.6 is a C.sub.5 -C.sub.9 alkyl group which may have a branch or a double bond, or a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group.
Priority Claims (2)
Number |
Date |
Country |
Kind |
62-18820 |
Jan 1987 |
JPX |
|
62-65352 |
Mar 1987 |
JPX |
|
Parent Case Info
This is a continuation of application Ser. No. 07/460,830 filed Sep. 12, 1989, now abandoned which is a continuation-in-part of application Ser. No. 07/149,445 filed Jan. 28, 1988, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3830578 |
Samuelsson |
Sep 1974 |
|
5166174 |
Ueno |
Nov 1992 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
460830 |
Sep 1989 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
149445 |
Jan 1988 |
|